Biogen Inc (BUE:BIIB)
ARS 18636 201.5 (1.09%) Market Cap: 28.98 Til Enterprise Value: 34.17 Til PE Ratio: 28.13 PB Ratio: 2.14 GF Score: 49/100

Biogen Inc Live Discussion of Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD Transcript

Mar 10, 2021 / 04:00PM GMT
Release Date Price: ARS3070 (-2.57%)
Yona Levites

Welcome to the live discussion of the -- symposium, Abeta-targeting therapies in AD #1. So my name is Yona Levites. I'm from Center for Translational Research in Neurodegenerative Diseases in University of Florida. And my co-moderator is Dr. Luka Kulic, and he will introduce himself, and then all the members of our discussion will introduce themselves.

Luka Kulic

Thank you very much, Yona. Yes, I'm Luka Kulic. I'm a neurologist by training and am a medical director, working at Roche Pharma Research and Early Development in Basel, and leading several Alzheimer's disease programs approach. Then I'll hand over to Laura.

Laura Nisenbaum

Thank you. My name is Laura Nisenbaum. It's a pleasure for me to be part of this session. I really appreciate the invitation. I lead the Diagnostic Pathway Group at Biogen and am also responsible for the biomarker strategy for aducanumab. Thanks.

Luka Kulic

Michelle? Sorry.

Michelle Gee

Okay. I'm Michelle Gee, and I'm

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot